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Abstract 
The extracellular signal–regulated kinase (ERK) signaling pathway is constitutively 
activated in many human tumor cell types.  Given the cytoprotective role of this pathway, 
we examined whether its specific blockade might sensitize human tumor cells to the 
induction of apoptosis by various anticancer drugs.  Although blockade of ERK signaling 
alone did not induce substantial cell death, it resulted in marked and selective 
enhancement of the induction of apoptosis by microtubule-destabilizing agents in tumor 
cells in which the ERK pathway is constitutively activated.  The synergistic activation of 
c-Jun NH2-terminal kinase by the combination of an ERK pathway inhibitor and a 
microtubule-destabilizing agent appeared to be responsible, at least in part, for this effect.  
These results suggest that administration of the combination of an ERK pathway inhibitor 
and a microtubule-destabilizing agent is a potential chemotherapeutic strategy for the 
treatment of tumor cells with constitutive activation of the ERK pathway. 
 





The extracellular signal–regulated kinase (ERK) pathway is activated in a variety of 
cell types by diverse extracellular stimuli and is among the most extensively studied of 
signaling pathways that connect various membrane receptors to the nucleus [1, 2].  
Activation of the ERK pathway is triggered by GTP loading of Ras at the plasma 
membrane, which is followed by sequential activation of a series of protein kinases 
including a member of the Raf family (such as Raf-1), mitogen-activated protein (MAP) 
kinase or ERK kinase (MEK) 1 and 2, and ERK1 and ERK2.  Activated ERK1/2 then 
phosphorylates various downstream substrates that contribute to the regulation of a wide 
range of cellular processes such as proliferation, differentiation, survival, and motility. 
Mechanisms for precise spatiotemporal control of intracellular signaling pathways 
have evolved to ensure homeostasis in multicellular organisms.  Inappropriate activation 
of these pathways underlies several refractory diseases, with aberrant activation of the 
ERK pathway having been shown to be a key contributing factor to many types of human 
cancer [3, 4].  In particular, overexpression or activating mutation of the epidermal 
growth factor receptor (EGFR) gene (in tumors of the lung, breast, colon, ovary, and 
bladder) [5], activating mutation of RAS (in tumors of the pancreas, colon, and lung) [6], 
and activating mutation of RAF (in melanomas and tumors of the colon, ovary, and 
thyroid) [7] have been associated with cancer and found to result in the activation of 
MEK1/2 and ERK1/2 in most cases.  Inhibition of the ERK pathway thus represents a 
promising strategy for cancer treatment [8, 9]. 
We have previously shown that specific blockade of the ERK pathway by MEK 
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inhibitors results in marked suppression not only of the proliferation [10] but also of the 
invasiveness [11] of tumor cells in which the pathway is constitutively activated.  
However, blockade of the ERK pathway by itself was found to be largely cytostatic, rather 
than cytotoxic, resulting in only a moderate induction of apoptosis in these tumor cells 
[10]. Efficient induction of apoptotic cell death is essential for the development of 
effective cancer chemotherapy [9]. 
Combination therapy based on cytotoxic agents with nonoverlapping toxicities is a 
key approach to cancer treatment, being generally driven by safety considerations.  
Interruption of the cytoprotective ERK pathway by MEK inhibitors has thus been 
proposed as a means to enhance the action of cytotoxic anticancer agents [12].  
Consistent with this notion, the chemotherapeutic effects of doxorubicin and paclitaxel 
were found to be enhanced by the MEK inhibitor U0126 in H460 human non–small cell 
lung cancer cells [13].  We have also recently shown that the MEK inhibitor PD184352 
enhances the induction of apoptosis by histone deacetylase inhibitors in a variety of tumor 
cells with constitutive activation of the ERK pathway [14]. 
We now show that blockade of the ERK pathway results in marked enhancement of 
the cytotoxic effect of microtubule-destabilizing agents in tumor cells in which the 
pathway is constitutively activated.  The combination of an ERK pathway inhibitor with 
a microtubule-destabilizing drug induced synergistic activation of c-Jun NH2-terminal 
kinase (JNK), with this effect appearing to be responsible, at least in part, for the enhanced 
induction of cell death. 
 
 5
Materials and Methods 
 
 Materials.  Vincristine, paclitaxel, and cytosine β-D-arabinofuranoside (Ara-C) were 
obtained from Sigma; etoposide (VP-16), cisplatin, and doxorubicin were from Wako 
(Osaka, Japan); and SP600125 was from Biomol.  PD184352 were synthesized as 
described previously [11].  TZT-1027 and vinorelbine were kindly provided by Teikoku 
Hormone (Kawasaki, Japan).  Antibodies to ERK1/2 and to EGFR were from Santa Cruz 
Biotechnology; those to diphosphorylated ERK1/2, to Tyr1173-phosphorylated EGFR, and 
to β-actin were from Sigma; and those to Asp175-cleaved caspase-3, to JNK, and to 
diphosphorylated JNK were from Cell Signaling Technology. 
 Cell culture and flow cytometry.  Human tumor cell lines T24 [bladder carcinoma; 
H-Ras(G12V)], HT1080 [fibrosarcoma; N-Ras(Q61K)], PC-9 [lung adenocarcinoma; 
EGFR(ΔE746–A750)], HeLa S3 (cervical adenocarcinoma), PC3 (prostate 
adenocarcinoma), Colo320 (colon adenocarcinoma), WiDr [colon adenocarcinoma; 
B-Raf(V600E)], TCO [colon adenocarcinoma; B-Raf(V600E)], A549 [lung 
adenocarcinoma; K-Ras(G12S)], H1650 [lung adenocarcinoma; EGFR(ΔE746–A750)], 
and II-18 [lung adenocarcinoma; EGFR(L858R)] were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum [4].  Cells exposed to 
various reagents were harvested by treatment with trypsin, fixed with 70% ethanol, treated 
with DNase-free RNase A (100 µg/ml, Sigma), stained with propidium iodide (20 µg/ml), 
and analyzed for DNA content with the use of a FACSCalibur flow cytometer and Cell 
Quest Pro software (Becton Dickinson) [10]. 
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 Immunoblot analysis.  Cell lysates were prepared as described previously [10, 11] 
and fractionated by SDS-polyacrylamide gel electrophoresis, and the separated proteins 
were transferred to a polyvinylidene difluoride membrane and probed with primary 
antibodies and horseradish peroxidase–conjugated secondary antibodies (Promega).  
Immune complexes were visualized with enhanced chemiluminescence reagents (GE 
Healthcare Bio-Sciences). 
 Immunofluorescence microscopy.  Cells were fixed with methanol at –20ºC and 
stained with antibodies to Asp175-cleaved caspase-3 (1/100 dilution) and Alexa Fluor 
488–conjugated secondary antibodies (1/200 dilution, Molecular Probes) [15].  The 
appearance of phosphatidylserine on the extracellular side of the plasma membrane and 
membrane permeability were evaluated by staining with annexin V and propidium iodide, 
respectively, with the use of an Annexin-V-Fluos staining kit (Roche Diagnostics).  
Condensation of nuclear DNA was also examined by staining with 
4',6-diamidino-2-phenylindole (DAPI).  Cells were observed with the use of an 
Axioskop2 Plus fluorescence microscope (Carl Zeiss). 
 RNA interference.  The sequences 5′-GGGCCTACAGAGAGCTAGTTCTTAT-3′ 
and 5′-CCAACTGTGAGGAATTATGTCGAAA-3′ were designed to generate small 
interfering RNA (siRNA) duplexes specific for human JNK1 and JNK2 mRNAs, 
respectively; the scrambled oligoribonucleotide 
5′-GGGATACAGAGCGATTGCTTCCTAT-3′ was used as a control (Invitrogen).  
Subconfluent cultures of T24 cells were transfected with siRNA (50 nM) for 48 h with the 
use of the LipofectAMINE 2000 reagent (Invitrogen). 
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Results and Discussion 
 
Blockade of the ERK pathway sensitizes tumor cells to the induction of cell death by 
microtubule-destabilizing agents.  We have previously shown that specific blockade of 
the ERK pathway by MEK inhibitors such as PD98059 and PD184352 completely 
suppresses the growth of tumor cells in which the pathway is constitutively activated.  
However, blockade of the ERK pathway by itself resulted in only a moderate induction of 
cell death in these tumor cells [10].  Thus, although treatment of T24 cells with PD98059 
(50 µM) or PD184352 (10 µM) totally suppressed the activation of ERK1/2 as well as cell 
proliferation (Fig. 1A), it did not increase the proportion of dead cells with a fractional 
DNA content (cells in sub-G1 phase) (Fig. 1B), which is a characteristic feature of 
apoptotic cell death [16].  Furthermore, the MEK inhibitor–induced suppression of cell 
growth was reversible, with cells resuming proliferation after removal of the inhibitor (Fig. 
1A).  Induction of cell death is essential for the development of effective cancer 
chemotherapy. 
To provide a basis for the development of new chemotherapeutic strategies against 
cancer, we examined whether specific blockade of the ERK pathway might sensitize 
tumor cells to the cytotoxic action of chemotherapeutic agents by promoting cell death.  
Each of the anticancer drugs examined (Ara-C, VP-16, cisplatin, doxorubicin, vincristine, 
and paclitaxel) induced the death of T24 and HT1080 cells, with the proportion of cells in 
sub-G1 phase increasing to between 40 and 80% after treatment with optimal drug 
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concentrations for more than 48 h (Fig. 1D, data not shown).  To examine the effect of 
ERK pathway inhibition on death induction by these anticancer drugs, we therefore treated 
the tumor cells with suboptimal drug concentrations that increased the proportion of cells 
in sub-G1 phase to ~20% after 48 h (Fig. 1B, C). 
PD98059 markedly enhanced the induction of cell death by vincristine in both T24 
and HT1080 cells (Fig. 1B, C).  This effect of PD98059 on death induction by vincristine 
was most pronounced at low concentrations of the latter drug in T24 (≤3 nM) and PC-9 
(≤10 nM) cells; under such conditions, vincristine by itself exhibited only a small 
cytotoxic effect in these cells (Fig. 1D).  In contrast, the effect of PD98059 on the 
cytotoxicity of Ara-C, VP-16, cisplatin, or doxorubicin was suppressive or differed 
between tumor cell lines (Fig. 1C).  Although PD98059 potentiated the induction of cell 
death by paclitaxel in these tumor cells [17], the effect was less pronounced than that 
observed with vincristine (Fig. 1C).  In subsequent experiments, we therefore focused on 
the effect of ERK pathway inhibition on the induction of cell death by 
microtubule-destabilizing agents. 
PD98059 markedly enhanced the induction of cell death by low concentrations of 
vincristine in a wide variety of tumor cells in which the ERK pathway is constitutively 
activated, including WiDr and TCO cells with Raf activation; HT1080, A549, and T24 
cells with Ras activation; and H1650, PC-9, and II-18 cells with EGFR activation (Fig. 2A, 
C).  It had no such effect in tumor cells in which the ERK pathway is not constitutively 
activated, including HeLa S3, PC3, and Colo320 cells.  Blockade of the ERK pathway 
not only by PD98059 but also by PD184352 or U0126 (10 µM) enhanced the cytotoxicity 
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of structurally different microtubule-destabilizing agents (Fig. 2B, data not shown), 
including vincristine, vinorelbine, and TZT-1027 [18].  Furthermore, treatment of II-18 
cells with gefitinib, a potent EGFR tyrosine kinase inhibitor [19], abolished the 
autophosphorylation of EGFR as well as markedly inhibited ERK1/2 activation and 
enhanced the induction of cell death by vincristine (Fig. 2C).  Together, these results 
indicated that blockade of the ERK pathway not only by a MEK inhibitor (directly) but 
also by an EGFR inhibitor (indirectly) sensitizes tumor cells to the induction of cell death 
by microtubule-destabilizing agents. 
 
The combination of an ERK pathway inhibitor and a low concentration of 
microtubule-destabilizing agent induces apoptosis mediated in part by JNK.  To 
characterize the cell death induced by the combination of an ERK pathway inhibitor and a 
low concentration of microtubule-destabilizing agent, we examined several markers of 
apoptosis in T24 cells.  The combination of PD98059 and vincristine (3 nM) induced a 
marked increase in the proportion of cells manifesting DNA condensation (as revealed by 
DAPI staining), those displaying phosphatidylserine at the cell surface in the absence of 
membrane permeability (as revealed by staining with annexin V and propidium iodide), 
and those expressing the activated form of caspase-3 (Fig. 3A), all of which are 
characteristics of the early phase of apoptotic cell death [20].  Immunoblot analysis also 
revealed that the drug combination induced the cleavage (activation) of caspase-3 to yield 
19- and 17-kDa fragments (Fig. 3B).  These results thus indicate that apoptosis is the 
major mechanism of cell death induced by the combination of PD98059 and a low 
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concentration of vincristine in T24 cells. 
The net balance of signaling by the cytoprotective ERK1/2 pathway and the 
stress-related JNK1/2 and p38 MAP kinase pathways has been suggested to determine 
whether cells survive or undergo apoptotic cell death on exposure to various insults [21].  
To investigate the molecular mechanism by which MEK inhibitors enhance the induction 
of apoptosis by vincristine, we examined the activation status of these kinases in T24 cells 
exposed to PD98059, 3 nM vincristine, or the combination of these agents.  Although 
vincristine alone, but not PD98059, induced the activation of JNK, the extent of 
vincristine-induced JNK activation was greatly increased by the presence of the MEK 
inhibitor (Fig. 3B).  Furthermore, the addition of 10 µM SP600125, a specific inhibitor of 
JNK [22], suppressed the induction of cell death by the combination of vincristine and 
PD98059 (Fig. 3C).  In contrast, vincristine (3 nM) induced a slight activation of p38 
MAP kinase in T24 cells and this effect was not enhanced substantially by PD98059 (data 
not shown).  These results thus suggested that JNK mediates the apoptotic cell death 
induced by the combination of a MEK inhibitor and a low concentration of 
microtubule-destabilizing agent. 
Finally, we examined the effect of RNA interference–mediated depletion of JNK1/2 
on the induction of apoptosis by PD98059 and vincristine (3 nM) in T24 cells.  
Immunoblot analysis revealed that transfection of the cells with siRNAs specific for JNK1 
or JNK2 mRNAs resulted in pronounced and preferential depletion of the 46- and 54-kDa 
JNK isoforms, respectively (Fig. 3C).  Depletion of either JNK1 or JNK2 substantially 
inhibited the induction of apoptotic cell death by the combination of PD98059 and 
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vincristine; depletion of JNK2 appeared to be more effective in this regard than that of 
JNK1.  Furthermore, depletion of both JNK1 and JNK2 suppressed the induction of cell 
death by the combination of PD98059 and vincristine more markedly.  These results thus 
suggest that the cell death induced by the combination of PD98059 and vincristine is 
mediated, at least in part, by JNK1 and JNK2.  The precise mechanism by which such a 
drug combination induces synergistic activation of JNK1/2 remains to be elucidated. 
We have now shown that, whereas specific blockade of the ERK pathway by itself 
does not induce substantial apoptotic cell death, it markedly sensitizes tumor cells to the 
induction of cell death by microtubule-destabilizing agents.  The synergistic induction of 
cell death by the combination of an ERK pathway inhibitor and a low concentration of 
microtubule-destabilizing agent was observed in many tumor cell types in which the ERK 
pathway is constitutively activated.  Furthermore, the combination of an ERK pathway 
inhibitor and a microtubule-destabilizing agent induced synergistic activation of JNK1/2, 
which appeared to mediate, at least in part, the synergistic induction of apoptotic cell death 
by the combination of these agents.  Together, our results indicate that administration of 
such a drug combination is a promising chemotherapeutic strategy for the treatment of 
tumors in which the ERK pathway is constitutively activated. 
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Figure 1. Selective potentiation by MEK inhibitors of the death-inducing effect of 
vincristine in tumor cells.  (A) T24 cells were incubated for the indicated times in the 
absence (open circles) or presence (closed circles) of 10 µM PD184352.  The cells in 
some dishes were first exposed to PD184352 after culture for 2 days (closed squares), 
whereas the PD184352-containing medium of some dishes was replaced with drug-free 
medium after culture for 2 days (gray circles) or 4 days (gray squares), as indicated by the 
arrowheads.  Cells were harvested by exposure to trypsin, and viable cells were counted 
with the use a hemocytometer after staining with trypan blue (Left).  T24 cells were 
treated with 10 µM PD184352 (PD) for the indicated times, after which cell lysates (20 µg 
of protein) were subjected to immunoblot analysis with antibodies to total or 
phosphorylated (P) forms of ERK1/2 (Right).  Open and closed arrowheads indicate 
phosphorylated and nonphosphorylated forms, respectively, of ERK1/2.  (B) T24 cells 
were incubated for 12, 24, or 48 h with the indicated agents in the absence (–) or presence 
(+) of 50 µM PD98059 and were then analyzed for DNA content by flow cytometry.  
VCR, vincristine; PTX, paclitaxel; CDDP, cisplatin; DXR, doxorubicin.  (C) T24 or 
HT1080 cells were incubated for 48 h with the indicated agents in the absence or presence 
of 50 µM PD98059 and were then analyzed as in (B) for the proportion of cells in sub-G1 
phase.  (D) T24 or PC-9 cells were incubated for 48 h with the indicated concentrations 
of vincristine in the absence or presence of 50 µM PD98059 and were then analyzed for 
the proportion of cells in sub-G1 phase.  Data in (A) and (B) are representative of three 
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separate experiments; those in (C) and (D) are means ± SD from three separate 
experiments, each performed in duplicate. 
 
Figure 2. Potentiation of the death-inducing effect of microtubule-destabilizing 
agents by blockade of the ERK pathway in tumor cells in which the pathway is 
constitutively activated.  (A) The indicated tumor cell lines were incubated in the 
absence (Control) or presence of 50 µM PD98059 (PD), vincristine (VCR: 3 nM for HeLa 
S3, TCO, and A549 cells; 10 nM for PC3, Colo320, and H1650 cells; 30 nM for WiDr 
cells), or both agents for 48 h, after which the proportion of cells in sub-G1 phase was 
determined by flow cytometry.  Lysates of untreated cells (20 µg of protein) were 
subjected to immunoblot analysis with antibodies to total or phosphorylated forms of 
ERK1/2 (Inset).  (B) T24 cells were incubated with the indicated agents for 48 h, after 
which the proportion of cells in sub-G1 phase was determined.  PD98, PD98059; PD18, 
PD184352; VNR, vinorelbine; TZT, TZT-1027.  (C) II-18 cells were incubated for 48 h 
with the indicated concentrations of vincristine in the absence (–) or presence (+) of 50 
µM PD98059 (PD) or 100 nM gefitinib (Gef), after which the proportion of cells in 
sub-G1 phase was determined.  II-18 cells were also incubated in the absence (Control) or 
presence of 50 µM PD98059 or 100 nM gefitinib for 24 h, after which cell lysates (20 µg 
of protein) were subjected to immunoblot analysis with antibodies to phosphorylated or 
total forms of EGFR or ERK1/2 (Inset).  All quantitative data are means ± SD from three 
separate experiments, each performed in duplicate. 
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Figure 3. Role of JNK in apoptotic cell death induced by the combination of PD98059 
and vincristine in T24 cells.  (A) Cells were incubated for 24 h in the absence (Control) 
or presence of 50 µM PD98059 (PD), 3 nM vincristine (VCR), or both agents and were 
then fixed and subjected to staining with DAPI, with annexin V and propidium iodide (PI), 
or with antibodies to the cleaved form of caspase-3.  Bar, 100 µm.  (B) Cells were 
incubated for the indicated times in the absence (C) or presence of 50 µM PD98059, 3 nM 
vincristine, or both agents, after which cell lysates (20 µg of protein) were subjected to 
immunoblot analysis with antibodies to phosphorylated or total forms of JNK or ERK1/2, 
to the cleaved form of caspase-3, or to β-actin (loading control).  Open arrowheads 
indicate phosphorylated forms of JNK1/2, phosphorylated forms of ERK1/2, or cleaved 
fragments (19 and 17 kDa) of caspase-3; closed arrowheads indicate β-actin and 
nonphosphorylated forms of JNK1/2 and ERK1/2.  (C) Cells were incubated for 48 h 
with or without 10 µM SP600125 and in the absence (Control) or presence of 50 µM 
PD98059, 3 nM vincristine, or both agents, after which they were analyzed for DNA 
content by flow cytometry.  (D) Cells transfected with siRNAs specific for JNK1 or 
JNK2 mRNAs (alone or together) or with a control siRNA were incubated for 24 h in the 
absence (Control) or presence of 50 µM PD98059, 3 nM vincristine, or both agents.  The 
cells were then analyzed for DNA content by flow cytometry.  Lysates (20 µg of protein) 
of the transfected cells were subjected to immunoblot analysis with antibodies to JNK or 
to β-actin (Inset).  Data in (A) and (B) are representative of three separate experiments; 
quantitative data in (C) and (D) are means ± SD from three separate experiments, each 
performed in duplicate 



